The Columbia University Digestive and Liver Disease Research Center

哥伦比亚大学消化和肝脏疾病研究中心

• 批准号: 10443133
• 负责人: Robert F. Schwabe
• 金额: $ 122.99万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-30 至 2027-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10443133
• 关键词: Appointment; Automobile Driving; Basic Science; Bioinformatics; Biological Specimen database; Biology; Cell Communication; Cells; Clinical; Clinical Research; Collaborations; Collection; Communities; Core Facility; Data; Detection; Digestive System Disorders; Direct Costs; Discipline; Disease; Education; Educational workshop; Effectiveness; Ensure; Environment; Epithelial; Epithelial Cells; Esophagus; Evolution; Functional disorder; Funding; Future; Goals; Grant; Growth; Homeostasis; Hospitals; Inflammation; Institution; Joints; Link; Liver; Liver diseases; Measures; Mentors; Metabolism; Mission; Morbidity - disease rate; National Institute of Diabetes and Digestive and Kidney Diseases; Natural regeneration; New York; Organ; Organoids; Pancreas; Pathway interactions; Patients; Physiology; Presbyterian Church; Prevention; Publications; Research; Research Methodology; Research Personnel; Science; Scientist; Services; Structure; Training; Training and Education; Translations; United States National Institutes of Health; Universities; Vision; base; bioimaging; clinical application; clinical translation; clinically relevant; diversity and equity; empowered; equity diversity and inclusion; gastrointestinal; improved; innovation; inter-institutional; investigator training; member; mortality; multidisciplinary; next generation; patient population; programs; single cell analysis; success; symposium; therapeutic target

SUMMARY Since its formal inception in 2019, the Columbia University Digestive and Liver Disease Research Center (CU- DLDRC) has brought together an interdisciplinary group of highly accomplished basic, translational and clinical researchers with complementary backgrounds from different departments and campuses and the New York Presbyterian Hospital. The CU-DLDRC reflects vibrant growth in digestive disease science over the last two decades, paired with exceptional institutional support and a dynamic scientific environment at Columbia University. The CU-DLDRC’s vision is to contribute to improved prevention, detection and therapy of digestive diseases through the application of creative concepts, cutting-edge research methods, innovation and multi- disciplinary team science, with a strong emphasis on clinical relevance and translation. The CU-DLDRC includes 49 digestive-focused members (30 full, 19 associate) with NIH funding of $20.8M direct costs (35.6% from NIDDK). The central theme “Epithelial cells and their interactions in digestive homeostasis and disease”, reflects the passion and expertise of its members and its key role in digestive diseases. The broad coverage of digestive organs under this theme is predicated upon the conceptual framework that many disease-driving pathways, cell- cell interactions and therapeutic targets are shared across digestive organs. Guided by these principles, digestive disease research at Columbia has witnessed significant growth and impact, fruitful collaborations and joint publications and grants to a degree that would not have been achieved by studies in single digestive organs. The Administrative Core ensures success and effectiveness of the CU-DLDRC through management of its research base, operational oversight, scientific vision, innovation, and structures and activities that stimulate translational digestive science with maximum member benefits (Aim 1). The four biomedical cores offer a suite of closely linked state-of-the-art core facilities that span from clinical biospecimens and databases to cutting- edge bioinformatics, organoid platforms and advanced bioimaging, empowering members to investigate epithelial cells and their interactions; these powerful research methods will be linked the breadth of clinical expertise and biospecimens via organ-focused clinical-basic teams (Aim 2). The Pilot and Feasibility program, that to date has funded seven investigators with an exceptional rate of return, will promote impactful basic and clinical projects, thereby promoting new investigators, innovation and the integration of excellence from other fields (Aim 3). The Enrichment Program will stimulate intellectual exchange within our center and with the national digestive community through seminars, an annual retreat, and basic-clinical symposia; support new investigators and training through a formal mentoring program and workshops; and promote Diversity, Equity and Inclusion (DEI) in all components and activities of the CU-DLDRC through a DEI delegate (Aim 4). Through these Aims, the CU-DLDRC will make impactful contributions to digestive disease research and serve our patients.

概括 自2019年正式成立以来，哥伦比亚大学消化和肝脏疾病研究中心（CU- DLDRC）汇集了一支由基础、转化和临床方面卓有成就的跨学科小组 来自不同院系、校园和纽约的具有互补背景的研究人员 长老会医院。CU-DLDRC 反映了过去两年消化疾病科学的蓬勃发展。 几十年来，加上哥伦比亚大学卓越的机构支持和充满活力的科学环境 CU-DLDRC 的愿景是为改善消化系统疾病的预防、检测和治疗做出贡献。 通过应用创造性的理念、前沿的研究方法、创新和多元的方法来治疗疾病 CU-DLDRC 包括学科团队科学，重点强调临床相关性和转化。 49 名专注于消化的会员（30 名正式会员，19 名准会员）获得 NIH 资助，直接费用为 2080 万美元（35.6% 来自 NIDDK）的中心主题“上皮细胞及其在消化稳态和疾病中的相互作用”反映了 其成员的热情和专业知识及其在消化系统疾病中的关键作用。 该主题下的器官基于许多疾病驱动途径、细胞- 在这些原则的指导下，细胞相互作用和治疗靶点在消化器官中是共享的。 哥伦比亚大学的消化疾病研究具有显着的增长和影响力、富有成效的合作和 联合出版物和资助的程度是单一消化器官研究无法达到的。 行政核心通过其管理确保 CU-DLDRC 的成功和有效性 研究基地、运营监督、科学愿景、创新以及刺激的结构和活动 具有最大会员利益的转化消化科学（目标 1）。 紧密相连的最先进的核心设施，涵盖从临床生物样本和数据库到切割 边缘生物信息学、类器官平台和先进的生物成像，使会员能够进行调查 上皮细胞及其相互作用；这些强大的研究方法将与临床广泛联系起来 通过以器官为中心的临床基础团队提供专业知识和生物样本（目标 2）。 迄今为止，该基金已资助七名研究人员，回报率极高，将促进有影响力的基础和 临床项目，从而促进新的研究人员、创新和整合其他人的优秀成果 丰富项目将促进我们中心内部以及与国家的知识交流。 通过研讨会、年度静修会和基础临床研讨会支持消化界； 通过正式的指导计划和研讨会进行培训；并促进多元化、公平和包容性 (DEI) 通过 DEI 代表参与 CU-DLDRC 的所有组成部分和活动（目标 4）。 CU-DLDRC 将为消化疾病研究做出有影响力的贡献并为我们的患者服务。